Group 1 - The company ST峡创 will be suspended from trading for one day on August 13 and will resume trading on August 14, with its stock name changing from "ST峡创" to "海峡创新" [1] - The company received an administrative penalty notice from the Zhejiang Securities Regulatory Bureau on May 10, 2024, leading to a risk warning on its stock starting May 14, 2024 [1] - The risk warning was related to the company’s previously controlled entity, 好医友医疗科技有限公司, which inflated revenue through fictitious consultation services, resulting in a reported revenue inflation of 75.34 million yuan in 2018 and 47.12 million yuan in the first half of 2019 [1] Group 2 - The Zhejiang Securities Regulatory Bureau imposed a fine of 600,000 yuan on ST峡创 and issued warnings to several executives, including fines of 300,000 yuan for the former chairman and vice president [2] - The company has made retrospective adjustments to its financial reports concerning the administrative penalty and currently does not face any other risk warnings [2] - In a recent performance briefing, the company stated its commitment to focusing on its core business and advancing in the smart city and smart healthcare sectors to enhance overall value and competitiveness [2]